Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR008693)
Formula
SVG example
O-methylation
Reactant Methyldopate Hydrochloride Product 3-O-methyl-alpha-methyldopa
Reactant Info Product Info
Metabolic Enzyme Catechol O-methyltransferase (COMT) DME Info
Metabolic Type Conjugation - O-methylation
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR008695 Methyldopate Hydrochloride 3,4-Dihydroxyphenylacetone Multi-steps Reaction - Deamination; decarboxylation Methyldopate Hydrochloride [1], [2], [3]
MR008697 Methyldopate Hydrochloride Alpha-methyldopa-mono-O-sulfate Conjugation - Sulfation Methyldopate Hydrochloride [1], [2], [4]
MR008689 Methyldopate Hydrochloride Alpha-methyldopamine Reduction - Decarboxylation Methyldopate Hydrochloride [5], [4], [6], [1]
Other MR(s) Related to The Product of This MR
Other MR(s) That Produce The Product of This MR
MR ID Reactant Product MR Type Related Drug REF
MR001500 Levodopa 3-O-Methyldopa Conjugation - Methylation Levodopa [7], [8], [9], [10]
Other MR(s) That Metabolize The Produtc of This MR
MR ID Reactant Product MR Type Related Drug REF
MR008694 3-O-methyl-alpha-methyldopa 3-O-methyl-alpha-methyldopa sulfate Conjugation - Sulfation Methyldopate Hydrochloride [11]
References
1 THE METABOLISM OF METHYLDOPA IN HYPERTENSIVE HUMAN SUBJECTS
2 Clinical pharmacokinetics of methyldopa
3 Reaction of dopa decarboxylase with alpha-methyldopa leads to an oxidative deamination producing 3,4-dihydroxyphenylacetone, an active site directed affinity label
4 Sulfate and methyldopa metabolism: metabolite patterns and platelet phenol sulfotransferase activity. Clin Pharmacol Ther. 1985 Mar;37(3):308-15.
5 Antihypertensive metabolites of alpha-methyldopa
6 The metabolism of 14 C-labelled -methyldopa in normal and hypertensive human subjects
7 Motor complications, levodopa metabolism and progression of Parkinson's disease Expert Opin Drug Metab Toxicol. 2011 Jul;7(7):847-55. doi: 10.1517/17425255.2011.575779.
8 Impact of the catechol-O-methyltransferase Val158Met polymorphism on the pharmacokinetics of L-dopa and its metabolite 3-O-methyldopa in combination with entacapone. J Neural Transm (Vienna). 2021 Jan;128(1):27-36. doi: 10.1007/s00702-020-02267-y.
9 Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia. Sci Adv. 2021 Jan 6;7(2):eabe5948. doi: 10.1126/sciadv.abe5948. Print 2021 Jan.
10 Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications. Pharmaceutics. 2021 Sep 3;13(9):1395. doi: 10.3390/pharmaceutics13091395.
11 DrugBank(Pharmacology-Metabolism):Methyldopate Hydrochloride

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.